Pharmacodynamics and pharmacokinetics of cisatracurium in geriatric surgical patients

Anesthesiology

Volumn 84, Issue 3, 1996, Pages 520-525

  Ornstein, Eugene ^a   Lien, Cynthia A ^b   Matteo, Richard S ^a   Ostapkovich, Noeleen D ^a   Diaz, Jaime ^a   Wolf, Karen B ^c  

^a Columbia University ^*  (United States)

^b Department of Obstetrics Gynecology   (United States)

^c Burroughs Wellcome Co   (United States)

Author keywords

Cisatracurium; Elderly; Neuromuscular relaxants; Pharmacodynamics; Pharmacokinetics

Indexed keywords

ATRACURIUM; CISATRACURIUM; FENTANYL; ISOFLURANE; NITROUS OXIDE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG POTENCY; GERIATRIC ANESTHESIA; HISTAMINE RELEASE; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MUSCLE TWITCH; MYOGRAPHY; NEUROMUSCULAR BLOCKING; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ATRACURIUM; HUMANS; MIDDLE AGED; NEUROMUSCULAR NONDEPOLARIZING AGENTS; STEREOISOMERISM;

EID: 0029975858     PISSN: 00033022     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000542-199603000-00005     Document Type: Article

References (30)

1. Belmont MR, Lien CA, Quessy S, Abou-Donia M, Abalos A, Eppich L, Savarese JJ: The clinical neuromuscular pharmacology of 51W89 in patients receiving nitrous oxide/opioid/barbiturate anesthesia. ANESTHESIOLOGY 1995; 82:1139-45
2. Lien CA, Belmont MR, Abalos A, Eppich L, Quessy S, Abou-Donia MM, Savarese JJ: The cardiovascular effects and histamine-releasing properties of 51W89 in patients receiving nitrous oxide/ opioid/barbiturate anesthesia. ANESTHESIOLOGY 1995; 82:1131-8
3. Nigrovic V, Banoub M: Pharmacokinetic modelling of a parent drug and its metabolite: Atracurium and laudanosine. Clin Pharmacokinet 1992; 22:396-408
4. Kent AP, Parker CJR, Hunter JM: Pharmacokinetics of atracurium and laudanosine in the elderly. Br J Anaesth 1989; 63:661-6
5. Kitts JB, Fisher DM, Canfell PC, Spellman MJ, Caldwell JE, Heier T, Fahey MR, Miller RD: Pharmacokinetics and pharmacodynamics of atracurium in the elderly. ANESTHESIOLOGY 1990; 72:272-5
6. Parker CJR, Hunter JM, Snowdon SL: Effect of age, sex and anaesthetic technique on the pharmacokinetics of atracurium. Br J Anaesth 1992; 69:439-43
7. Welch R, Brown A, Dahl R: In vitro degradation of cistatracurium in Sorensen buffer, rat, and human plasma. Clin Pharm Ther 1995; 58:132-4
8. Giltinan DM, Ruppert D: Fitting heteroscedastic regression models to individual pharmacokinetic data using standard statistical software. J Pharmacokinet Biopharm 1992; 17:601-14
9. Boxenbaum HJG, Riegelman S, Elashoff RM: Statistical estimation in pharmacokinetics. J Pharmacokinet Biopharm 1974; 2:121-48
10. Wagner J: Linear pharmacokinetic equations allowing direct calculation of many needed pharmacokinetic parameters from the coefficients and exponents of polyexponential equations which have been fitted to the data. J Pharmacokinet Biopharm 1976; 4:443-67
11. Dixon WJ, Massey FJJ: Introduction to Statistical Analysis. New York, McGraw Hill, 1969, p 328
12. Dixon WJ: Processing data outliers. Biometrics 1953; 9:74-89
13. Lowry KG, Mirakhur RK, Lavery GG, Clarke RSJ: Vecuronium and atracurium in the elderly: A clinical comparison with pancuronium. Acta Anaesthesiol Scand 1985; 29:405-8
14. Kisor D, Wargin W, Weatherley B, Schmith V, Ornstein E, Cook RD: Organ-independent Hofman elimination is the dominant clearance pathway of the neuromuscular blocking agent 51W89 in humans. Pharm Res 1994; 11:S335
15. Fisher DM, Canfell CP, Fahey MR, Rosen JI, Rupp SM, Sheiner LB, Miller RD: Elimination of atracurium in humans: Contributions of Hofmann elimination and ester hydrolysis versus organ-based elimination. ANESTHESIOLOGY 1986; 65:6-12
16. Ritschel WA: Pharmacokinetic approach to drug dosing in the aged. J Am Geriatr Soc 1976; 24:344-54
17. Wood M: Plasma drug binding: Implications for anesthesiologists. Anesth Analg 1986; 65:786-804
18. Hull CJ: A model for atracurium? Br J Anaesth 1983; 55:95-6
19. Nakashima E, Benet LZ: General treatment of mean residence time, clearance, and volume parameters in linear mammillary models with elimination from any compartment. J Pharmacokinet Biopharm 1988; 16:475-92
20. Shi WZ, Fahey MR, Fisher DM, Miller RD: Modification of central nervous system effects of laudanosine by inhalational anaesthetics. Br J Anaesth 1989; 63:598-600
21. Chapple DJ, Miller AA, Ward JB, Wheatley PL: Cardiovascular and neurological effects of laudanosine. Br J Anaesth 1987; 59:218-25
22. Parker CJR, Jones JE, Hunter JM: Disposition of infusions of atracurium and its metabolite, laudanosine, in patients in renal and respiratory failure in an ITU. Br J Anaesth 1988; 61:531-40
23. Bion JF, Bowden MI, Chow B, Honisberger L, Weatherley BC: Atracurium infusions in patients with fulminent hepatic failure awaiting liver transplantation. Intensive Care Med 1993; S94-8
24. Griffiths RB, Hunter JM, Jones RS: Atracurium infusions in patients with renal failure in an ITU. Anaesthesia 1986; 41:375-81
25. Yate PM, Flynn PJ, Arnold RW, Weatherly BC, Simmons RJ, Dopson T: Clinical experience and plasma laudanosine concentrations during the infusion of atracurium in the intensive therapy unit. Br J Anaesth 1987; 59:211-7
26. Peat SJ, Potter DR, Hunter JM: The prolonged use of atracurium in a patient with tetanus. Anaesthesia 1988; 43:962-3
27. Pollard BJ, Harper NJN, Doran BRH: Use of continuous prolonged administration of atracurium in the ITU to a patient with myasthenia gravis. Br J Anaesth 1989; 62:95-7
28. Gwinnutt CL, Eddelston JM, Edwards D, Pollard BJ: Concentrations of atracurium and laudanosine in cerebrospinal fluid and plasma in three intensive care patients. Br J Anaesth 1990; 65:829-32
29. Prielipp RC, Coursin DB, Scuderi PE, Prough DS, Vender JE, Murray MJ: Dose response, safety, and recovery profile of a new neuromuscular blocking drug, 51W89, in patients in the intensive care unit (abstract). ANESTHESIOLOGY 1994; 81:A258
30. Stevens WC, Dolan WM, Gibbons RT, White A, Eger EI II, Miller RD, deJong RH, Elashoff RM: Minimum alveolar concentration (MAC) of isoflurane with and without nitrous oxide in patients of various ages. ANESTHESIOLOGY 1975; 42:197-200